TuesdayJan 24, 2023 11:57 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses ‘Lifeblood’ of Phase 2 Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers in the brain and central nervous system, is enrolling patients in a phase 2 trial to evaluate the efficacy of its flagship drug candidate. The potentially pivotal trial will evaluate Berubicin for the treatment of glioblastoma multiforme (“GBM”), an aggressive brain tumor with an average overall survival rate of only 10-12 months. The company’s Chief Executive Officer John Climaco recently participated in the Virtual Investor “Ask the CEO” Event and discussed that enrollment in the trial was approaching 70 patients against a…

Continue Reading

TuesdayJan 24, 2023 11:32 am

BioMedNewsBreaks – MetAlert Inc. (MLRT) Approaching Inflection Point of Its Growth Curve

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, is launching a suite of wearable companion products to its innovative SmartSole shoe insole units. “The patented GPS-enabled SmartSole is a non-intrusive tracking device designed to monitor the location of people with cognitive memory disorders such as Alzheimer’s Disease who tend to get lost or wander. The tech-designed insole may also be used by people at risk of kidnapping, such as children, government employees and select professionals. A next-generation shoe insole branded SmartSole plus incorporates biometric sensors paired with smart analytics to…

Continue Reading

TuesdayJan 24, 2023 10:55 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Senior Medical Tech Veteran as New President

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has appointed Robert Eno to the newly created position of president. A senior medical technology executive, Eno will work to enhance the company’s strategic and operations capabilities. Eno brings a background of almost three decades experience in developing markets and commercializing disruptive medical technologies to his new role, where he will be essential in the company’s strategic direction, commercialization efforts, and day-to-day operations. Eno noted that he believes HeartBeam’s technology will be able to make a…

Continue Reading

TuesdayJan 24, 2023 10:05 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Closes on $4.1M Direct, Private Placement Offerings

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair, skin and sexual wellness, has closed on its previously announced registered direct offering and concurrent private placement. The offering includes the purchase and sale of 4,315,787 shares in a registered direct offering, with the concurrent private placement calling for JUPW to issue and sell a total of 8,631,574 warrants to the same investors. The warrants are to purchase up to one share of common stock each at an exercise price of $1 per share. According to the announcement, the private placement warrants will be exercisable six months after issuance. The…

Continue Reading

MondayJan 23, 2023 1:08 pm

BioMedNewsBreaks – Jupiter Wellness Inc.’s (NASDAQ: JUPW) Redeemable Digital Coupons Now Available for Shareholders of Record

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced availability of its redeemable digital coupons for shareholders of record to claim on Upstream’s trading app. Upon successful claim, shareholders may redeem the digital coupon for a gift package of company products valued at over $179 or trade with others globally on Upstream to bring new potential customers into the community. The announcement reads, “By incorporating Upstream’s Web3 digital coupons into our strategy, we aim to provide our shareholders with first-hand experience of our products and bring new potential customers into our community to drive…

Continue Reading

MondayJan 23, 2023 12:59 pm

BioMedNewsBreaks – QSAM Biosciences Inc. (QSAM) to Present at Emerging Growth Conference

QSAM Biosciences (OTCQB: QSAM) is developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases and conditions. The company today announced that it has been invited to present at the Emerging Growth Conference at 10:15 a.m. ET on Wednesday, Jan. 25, 2023. Leading QSAM’s presentation will be the company’s CEO Douglas Baum and other executive officers, who may subsequently open the floor for questions. Interested parties should visit https://ibn.fm/P2xIR to register to attend the conference and receive any updates. An archived webcast will be made available on EmergingGrowth.com and on the Emerging Growth YouTube…

Continue Reading

MondayJan 23, 2023 10:58 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug. According to the update, the study used an industry-standard animal model to compare weight loss in two groups of hamsters. Hamsters administered a mid-sized 0.66mg dose of the NanoAb three hours prior to infection experienced no significant weight loss over the six-day trial, whereas the untreated control group’s weight declined 12% on average, a highly statistically significant difference (p<0.0005). “We…

Continue Reading

FridayJan 20, 2023 12:25 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Reaches Pivotal Milestone to Advance ADI (TM) Technology

Aditxt (NASDAQ: ADTX) recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune Inc., and appointed Joachim-Friedrich Kapp, MD, Ph.D, a 30-year veteran of the pharmaceutical industry, as its chairman and CEO. “Dr. Kapp will be tasked with leading and developing the ADI(TM) immune modulation technology and ADI(TM)-100, Aditxt’s unique and potent antigen-specific immunotherapeutic technology drug candidate, toward clinical trials… Short for Apoptotic DNA Immunotherapy(TM), ADI(TM) is a nucleic acid-based technology platform that utilizes a novel antigen-specific approach to induce immune tolerance by mimicking the way the body naturally induces tolerance to its own tissues. The technology, the company…

Continue Reading

FridayJan 20, 2023 12:10 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Eying Broad Market Opportunities for Its Liposomal Joint Homing Peptide

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, recently revealed positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents. “Silo Pharma provided an update on the ongoing study as of Dec. 30, 2022. During the study, tests were conducted to evaluate the disease-suppressive effects of an SPU-21 peptide-guided anti-arthritis drug versus the drug alone. The drug used in the study was dexamethasone (“DEX”), a corticosteroid used for its anti-inflammatory and immunosuppressant effects. Earlier results of the same study successfully demonstrated that the…

Continue Reading

FridayJan 20, 2023 11:05 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Issues Correction Regarding $4.1M Registered Direct and Private Placement

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, on Thursday announced its entry into a definitive agreement with investors in a registered direct offering, as well as details surrounding a concurrent private placement. The company issued an update to the initial release to correct the final share count and closing date. The registered direct offering is for the purchase and sale of 4,315,787 shares. In a concurrent private placement, Jupiter Wellness also agreed to issue to the same investors a total of 8,631,574 warrants to purchase up to one share of common stock, each at…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000